Repositorio Dspace

Listar por tema "Heart Failure"

Listar por tema "Heart Failure"

Ordenar por:Orden:Resultados:

  • Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial 
    Anker, Stefan D.; Butler, Javed; Filippatos, Gerasimos; Khan, Muhammad Shahzeb; Ferreira, João Pedro; Bocchi, Edimar; Böhm, Michael; Brunner-La Rocca, Hans Pieter; Choi, Dong-Ju; Chopra, Vijay; Chuquiure-Valenzuela, Eduardo; Giannetti, Nadia; Gomez-Mesa, Juan Esteban; Janssens, Stefan; Januzzi, James L.; Gonzalez-Juanatey, Jose R.; Merkely, Bela; Nicholls, Stephen J.; Perrone, Sergio Víctor; Piña, Ileana L.; Ponikowski, Piotr; Senni, Michele; Seronde, Marie-France; Sim, David; Spinar, Jindrich; Squire, Iain; Taddei, Stefano; Tsutsui, Hiroyuki; Verma, Subodh; Vinereanu, Dragos; Zhang, Jian; Jamal, Waheed; Schnaidt, Sven; Schnee, Janet; Brueckmann, Martina; Pocock, Stuart J.; Zannad, Faiez; Packer, Milton; EMPEROR-Preserved Trial Committees and Investigators (Wiley, 2020-12)
    Aims: EMPEROR-Preserved is an ongoing trial evaluating the effect of empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF). This report describes the baseline characteristics of the ...
  • Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure 
    Packer, Milton; Anker, Stefan D.; Butler, Javed; Filippatos, Gerasimos; Pocock, Stuart J.; Carson, Peter; Januzzi, James L.; Verma, Subodh; Tsutsui, Hiroyuki; Brueckmann, Martina; Jamal, Waheed; Kimura, Karen; Schnee, Janet; Zeller, Cordula; Cotton, Daniel; Bocchi, Edimar; Böhm, Michael; Choi, Dong-Ju; Perrone, Sergio Víctor; EMPEROR-Reduced Trial Investigators (Massachusetts Medical Society, 2020-10-08)
    Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regarding the effects ...
  • Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved 
    Anker, Stefan D.; Butler, Javed; Usman, Muhammad Shariq; Filippatos, Gerasimos; Ferreira, João Pedro; Bocchi, Edimar; Böhm, Michael; Brunner-La Rocca, Hans Pieter; Choi, Dong-Ju; Chopra, Vijay; Chuquiure, Eduardo; Giannetti, Nadia; Gomez-Mesa, Juan Esteban; Janssens, Stefan; Januzzi, James L.; González-Juanatey, José R.; Merkely, Bela; Nicholls, Stephen J.; Perrone, Sergio Víctor; Piña, Ileana L. (Nature Publishing Company, 2022-12)
    The EMPEROR-Preserved trial showed that the sodium-glucose co-transporter 2 inhibitor empagliflozin significantly reduces the risk of cardiovascular death or hospitalization for heart failure (HHF) in heart failure patients ...
  • Emerging concepts in heart failure management and treatment: circulatory support with extracorporeal membrane oxygenation (ECMO) 
    Swedzky, Federico; Barbagelata, Alejandro; Perrone, Sergio Víctor; Kaplinsky, Edgardo; Ducharme, Anique (Bioexcel Publishing Ltd., 2023-01-04)
    Circulatory support with extracorporeal membrane oxygenation (ECMO) is being increasingly used in several critical situations but evidence of its impact on outcomes is inconsistent. Understanding of the specific indications ...
  • Emerging concepts in heart failure management and treatment: focus on current guideline-directed medical therapy for heart failure with reduced ejection fraction 
    Ospina González, Oscar Eduardo; Llanos Mejía, Diana Catalina; Kaplinsky, Edgardo; Barbagelata, Alejandro; Perrone, Sergio Víctor (Bioexcel Publishing, 2023-01-04)
    ne of the most relevant and differentiating aspects provided by the 2021 European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure is the retraction of the historical ...
  • Emerging concepts in heart failure management and treatment: focus on point-of-care ultrasound in cardiogenic shock 
    Ruben, Mariela; Molinas, María Sol; Paladini, Hugo; Khalife, Wissam; Barbagelata, Alejandro; Perrone, Sergio Víctor; Kaplinsky, Edgardo (Bioexcel Publishing Ltd, 2023-01-04)
    Point-of-care ultrasound (POCUS) plays a strategic role in the diagnostic and therapeutic evaluation of critically ill patients and, especially, in those who are haemodynamically unstable. In this context, POCUS allows a ...
  • Emerging concepts in heart failure management and treatment: focus on tachycardia-induced cardiomyopathy 
    Báez Cabanillas, María Victoria; Colque, Roberto; Tibaldi, Miguel Ángel; Kaplinsky, Edgardo; Perrone, Sergio Víctor; Barbagelata, Alejandro (Bioexcel Publishing, 2023-01-04)
    Tachycardia-induced cardiomyopathy is an entity characterized by reversible dysfunction of the left ventricle, which can be induced by different types of arrhythmia such as atrial fibrillation, atrial flutter, incessant ...
  • Emerging concepts in heart failure management and treatment: focus on vericiguat 
    Kaplinsky, Edgardo; Perrone, Sergio Víctor; Barbagelata, Alejandro (Bioexcel Publishing, 2023-01-04)
    The nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway is dysregulated in patients with heart failure (HF) resulting in myocardial and vascular dysfunction that contributes to ...
  • Empagliflozin in Heart Failure with a Preserved Ejection Fraction 
    Anker, Stefan D.; Butler, Javed; Gerasimos, Filippatos; Ferreira, João Pedro; Bocchi, Edimar; Böhm, Michael; Brunner-La Rocca, Hans Pieter; Choi, Dong-Ju; Chopra, Vijay; Chuquiure-Valenzuela, Eduardo; Giannetti, Nadia; Gomez-Mesa, Juan Esteban; Janssens, Stefan; Januzzi, James L.; Gonzalez-Juanatey, Jose R.; Merkely, Bela; Nicholls, Stephen J.; Perrone, Sergio Víctor; Piña, Ileana L.; EMPEROR-Preserved Trial Investigators (Massachusetts Medical Society, 2021-08-27)
    Background: Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure ...
  • Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial 
    Anker, Stefan D.; Butler, Javed; Filippatos, Gerasimos; Waheed, Jamal; Salsali, Afshin; Schnee, Janet; Kimura, Karen; Zeller, Cordula; Jyothis, George; Brueckmann, Martina; Zannad, Faiez; Packer, Milton; EMPEROR-Preserved Trial Committees and Investigators (Wiley, 2019-09-16)
    Background: The principal biological processes that characterize heart failure with a preserved ejection fraction (HFpEF) are systemic inflammation, epicardial adipose tissue accumulation, coronary microcirculatory ...
  • Multimorbidity in patients with acute heart failure across world regions and country income levels (REPORT-HF): a prospective, multicentre, global cohort study 
    Gerhardt, Teresa; Gerhardt, Louisa M.S.; Ouwerkerk, Wouter; Roth, Gregory A.; Dickstein, Kenneth; Collins, Sean P.; Cleland, John G.F.; Dahlstrom, Ulf; Ting Tay, Wan; Ertl, Georg; Hassanein, Mahmoud; Perrone, Sergio Víctor; Ghadanfar, Mathieu; Schweizer, Anja; Obergfell, Achim; Filippatos, Gerasimos; Lam, Carolyn S.P.; Tromp, Jasper; Angermann, Christiane E. (Elsevier, 2023-12-01)
    Background: Multimorbidity (two or more comorbidities) is common among patients with acute heart failure, but comprehensive global information on its prevalence and clinical consequences across different world regions and ...
  • Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF 
    Vaduganathan, Muthiah; Claggett, Brian L.; Desai, Akshay S.; Anker, Stefan D.; Perrone, Sergio Víctor; Janssens, Stefan; Milicic, Davor; Arango, Juan L.; Packer, Milton; Shi, Victor C.; Lefkowitz, Martin P.; McMurray, John J.V.; Solomon, Scott D. (Elsevier, 2020-01-28)
    Background: The period shortly after hospitalization for heart failure (HF) represents a high-risk window for recurrent clinical events, including rehospitalization or death. Objectives: This study sought to determine ...
  • Quality of life assessed 6 months after hospitalisation for acute heart failure: an analysis from REPORT-HF (international REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure) 
    McNaughton, Candace D.; McConnachie, Alex; Cleland, John G.; Spertus, John A.; Angermann, Christiane E.; Duklas, Patrycja; Tromp, Jasper; Lam, Carolyn S. P.; Filippatos, Gerasimos; Dahlstrom, Ulf; Dickstein, Kenneth; Schweizer, Anja; Perrone, Sergio Víctor; Hassanein, Mahmoud; Ertl, Georg; Obergfell, Achim; Ghadanfar, Mathieu; Collins, Sean P. (Wiley, 2022-04-16)
    Aims: Recovery of well-being after hospitalisation for acute heart failure (AHF) is a measure of the success of interventions and the quality of care but has rarely been quantified. Accordingly, we measured health status ...